載入中
NASDAQHealthcareBiotechnology
最新資料
US$3.74
−US$0.15 · -3.86%
Prelude Therapeutics, Inc. is a clinical-stage precision oncology company focused on identifying and developing innovative, targeted cancer treatments for patient populations with unmet medical needs. Its pipeline includes PRT543, currently undergoing Phase 1 clinical evaluation for certain solid tumors and myeloid malignancies. Another asset, PRT811, is also in Phase 1 trials, targeting various solid tumors, notably glioblastoma multiforme. The company is additionally progressing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a powerful and highly kinome-selective CDK9 inhibitor; PRT-SCA2, which is in preclinical development for several genomically selected cancers; PRT3645, a brain-penetrant molecule that precisely and effectively targets CDK4/6; and PRT-K4, another preclinical compound for solid tumors. Founded in 2016, the firm's headquarters are located in Wilmington, Delaware.
前收盤價
US$3.74
−US$0.15 · -3.86%
盤後
US$3.74
US$0.00 · 0.00%
10月12日 下午7:30 ET
盤中時間採用ET。市場資料可能有所延遲。
Prelude Therapeutics, Inc. is a clinical-stage precision oncology company focused on identifying and developing innovative, targeted cancer treatments for patient populations with unmet medical needs. Its pipeline includes PRT543, currently undergoing Phase 1 clinical evaluation for certain solid tumors and myeloid malignancies. Another asset, PRT811, is also in Phase 1 trials, targeting various solid tumors, notably glioblastoma multiforme. The company is additionally progressing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a powerful and highly kinome-selective CDK9 inhibitor; PRT-SCA2, which is in preclinical development for several genomically selected cancers; PRT3645, a brain-penetrant molecule that precisely and effectively targets CDK4/6; and PRT-K4, another preclinical compound for solid tumors. Founded in 2016, the firm's headquarters are located in Wilmington, Delaware.
日內區間
目前US$3.74
52週區間
目前US$3.74
盤中時間採用ET。市場資料可能有所延遲。
Prelude Therapeutics, Inc. is a clinical-stage precision oncology company focused on identifying and developing innovative, targeted cancer treatments for patient populations with unmet medical needs. Its pipeline includes PRT543, currently undergoing Phase 1 clinical evaluation for certain solid tumors and myeloid malignancies. Another asset, PRT811, is also in Phase 1 trials, targeting various solid tumors, notably glioblastoma multiforme. The company is additionally progressing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a powerful and highly kinome-selective CDK9 inhibitor; PRT-SCA2, which is in preclinical development for several genomically selected cancers; PRT3645, a brain-penetrant molecule that precisely and effectively targets CDK4/6; and PRT-K4, another preclinical compound for solid tumors. Founded in 2016, the firm's headquarters are located in Wilmington, Delaware.
日內區間
目前US$3.74
52週區間
目前US$3.74
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 1214萬 USD | 700萬 USD | — | — | — |
| 銷貨成本 | 171.1萬 USD | — | — | — | — |
| 毛利 | 1042.9萬 USD | 700萬 USD | — | — | — |
| 研究與開發 | 9430萬 USD | 1.18億 USD | 1.03億 USD | 9288.9萬 USD | 8677.8萬 USD |
| 銷售、一般及管理費用 | 2240.6萬 USD | 2871.9萬 USD | 2888.4萬 USD | 3065.1萬 USD | 2695.7萬 USD |
| 營業費用 | 1.15億 USD | 1.47億 USD | 1.32億 USD | 1.24億 USD | 1.14億 USD |
| 折舊和攤銷 | 171.1萬 USD | 177.2萬 USD | 116.9萬 USD | 132.4萬 USD | 91.5萬 USD |
| 營業利益 | −1.05億 USD | −1.4億 USD | −1.32億 USD | −1.24億 USD | −1.14億 USD |
| 淨利 | −9949.8萬 USD | −1.27億 USD | −1.22億 USD | −1.15億 USD | −1.12億 USD |
公司資料更新於 2026年10月13日。
近期已公布業績
近期已公布業績
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI847.74萬0.00%2.3兆 USD0.03%US$381.57-0.10%
iShares Russell 2000 ETFIWM278.99萬0.00%787.4億 USD0.19%US$277.9-0.37%
Vanguard Extended Market ETFVXF256.68萬0.00%954億 USD0.05%US$233.52-0.63%
iShares Russell 2000 Growth ETFIWO101.04萬0.01%139.17億 USD0.24%US$353.71-0.86%
Vanguard Russell 2000 ETFVTWO89.68萬0.00%180億 USD0.06%US$112.27-0.35%
iShares Micro-Cap ETFIWC34.3萬0.03%13.17億 USD0.60%US$181.66-0.73%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM23萬0.20%1.16億 USD0.73%US$15.8484-0.58%
Vanguard Russell 2000 Growth ETFVTWG16.88萬0.01%17億 USD0.06%US$258.28-0.85%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMVanguard Russell 2000 Growth ETFVTWGAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
